Med-tech leaders came together for a meeting of the minds at MassDevice’s first Big 100 Regional Roundtable in Waltham, Mass., July 11. Four CEOs, each representing an interesting and important sector of the life science industry – the fascinating juncture between orthopedics and minimally invasive techniques, genomics and personalized medicine, the cutting edge of bio-interactive nanotech coatings and the mid-cap medical device world – shared their thoughts on the particular challenges facing their businesses and the life sciences industry as a whole.
The participants were, from left to right:
- Richard Packer, CEO of ZOLL Medical Corp. (NSDQ:ZOLL)
Packer was named Zoll’s chairman and CEO in 1999, 16 years after the company got its start. A leader in the local medical device world and in the resuscitation industry, Zoll has grown to a $500 million dollar concern under Mr. Packer’s watch. He holds an MBA from the Harvard Business School and engineering degrees from Rensselaer Polytechnic Institute.
- Don Hardison, CEO of Good Start Genetics
Hardison has a broad background as an executive with both emerging, private firms and Fortune 500 companies. Prior to joining Good Start Genetics, he was an Executive in Residence at Flagship Ventures, where he explored new opportunities in the diagnostic space and worked with Flagship’s portfolio companies. Prior to joining Flagship, Mr. Hardison was an Executive Vice President & Chief Operating Officer at Laboratory Corporation of America in Burlington, North Carolina. He also served as President, CEO and Director of EXACT Corporation, an applied genomics/biotechnology company focused on the early detection of cancer.
- Brad Perriello, Executive Editor/Co-Founder of MassDevice.com (moderator)
- Scott Rader, CEO of IlluminOss Medical Inc.
Mr. Rader has two decades worth of experience in corporate and product development roles in the medical device industry. Prior to IlluminOss, he was CEO of Arsenal Medical and President and CEO of Bacchus Vascular (acquired by Covidien), a privately held company developing and commercializing minimally invasive devices to treat peripheral vascular disease. Before entering industry, Mr. Rader was an assistant professor of both ophthalmology and mechanical engineering at Johns Hopkins University and is a holder of several mechanical engineering and materials science degrees from Duke University.
- David Lucchino, CEO of Semprus Biosciences
Prior to co-founding Semprus in 2007, Lucchino was a Senior Associate at Polaris Venture Partners, a $3 billion venture capital fund based in Boston. Mr. Lucchino was involved in the fund’s investment in Athletes’ Performance, a global leader for integrated performance training, nutrition and physical therapy. He also co-founded and served as Managing Director of LaunchCyte, an investment firm that specializes in developing biomedical intellectual property.